Radiation Oncology Department, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo.
Department of Radiation Oncology and Proton Medical Research Center, University of Tsukuba, Ibaraki, Japan.
Int J Gynecol Cancer. 2018 Sep;28(7):1438-1445. doi: 10.1097/IGC.0000000000001305.
American Brachytherapy Society (ABS)-recommended interstitial brachytherapy (IBT) should be considered for bulky vaginal tumor thicker than 5 mm. The aim of this study was to evaluate the ABS consensus guideline for patients with severe vaginal invasion based on our long-term follow-up results.
METHODS/MATERIALS: The study included 7 patients with vaginal cancer and 14 patients with cervical cancer invading to the lower vagina. Based on prebrachytherapy magnetic resonance imaging findings, patients received intracavitary brachytherapy (ICT) for vaginal tumors 5 mm or less or IBT for vaginal tumors less than 5 mm. Nine patients received ICT and the remaining 12 patients received IBT. For dosimetric comparison, an experimental recalculation as the virtual IBT for patients actually treated by ICT, and vice versa, was performed.
The 5-year local control rate for all tumors was 89.4%. No differences in local control between ICT- and IBT-treated groups were observed (P = 0.21). One patient experienced a grade 3 rectal complication. There were no significant differences in the CTV D90 and rectum D2cc between the 2 groups (P = 0.13 and 0.39, respectively). In the dosimetric study of ICT-treated patients, neither the actual ICT plans nor the experimental IBT plans exceeded the limited dose for organs at risk, which were recommended in the guideline published from the ABS. In the IBT-treated patients, D2cc for bladder and rectum of the experimental ICT plans was significantly higher than for the actual IBT plans (P < 0.001 and <0.001, respectively), and 11 experimental ICT plans (92%) exceeded the limited dose for bladder and/or rectum D2cc.
Tumor control and toxicity after selected brachytherapy according to vaginal tumor thickness were satisfactory; IBT instead of ICT is recommended for patients with vaginal tumor thickness greater than 5 mm to maintain bladder and/or rectum D2cc.
美国近距离放射治疗协会(ABS)推荐对厚度大于 5 毫米的大块阴道肿瘤采用间质近距离放射治疗(IBT)。本研究的目的是基于我们的长期随访结果,评估 ABS 针对阴道广泛侵犯患者的共识指南。
方法/材料:本研究纳入 7 例阴道癌患者和 14 例侵犯阴道下段的宫颈癌患者。根据放化疗前磁共振成像(MRI)检查结果,对阴道肿瘤厚度为 5 毫米或以下的患者行腔内近距离放射治疗(ICBT),对阴道肿瘤厚度小于 5 毫米的患者行 IBT。9 例患者接受 ICBT,其余 12 例患者接受 IBT。为了进行剂量比较,对实际接受 ICBT 治疗的患者进行了虚拟 IBT 再计算,并对接受 IBT 治疗的患者进行了 ICT 再计算。
所有肿瘤的 5 年局部控制率为 89.4%。ICT 组和 IBT 组的局部控制率无差异(P=0.21)。1 例患者出现 3 级直肠并发症。2 组患者的 CTV D90 和直肠 D2cc 无显著差异(P=0.13 和 0.39)。在对接受 ICBT 治疗患者的剂量学研究中,无论是实际的 ICBT 计划还是实验性的 IBT 计划,均未超过 ABS 发布的指南中推荐的危及器官的限制剂量。在接受 IBT 治疗的患者中,实验性 ICBT 计划的膀胱和直肠 D2cc 明显高于实际 IBT 计划(P<0.001 和 <0.001),11 个实验性 ICBT 计划(92%)超过了膀胱和/或直肠 D2cc 的限制剂量。
根据阴道肿瘤厚度选择的近距离放射治疗后肿瘤控制和毒性反应令人满意;对于阴道肿瘤厚度大于 5 毫米的患者,建议采用 IBT 而不是 ICT,以保持膀胱和/或直肠 D2cc。